Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infliximab - Janssen Biotech

Next Previous
Drug Profile

Infliximab - Janssen Biotech

Alternative Names: cA2; CenTNF; Remicade; TA-650

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NYU Langone Medical Center
  • Developer Centocor; Janssen Biotech; Merck & Co; Mitsubishi Tanabe Pharma Corporation; National Jewish Medical and Research Center; Xian-Janssen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Ankylosing spondylitis; Behcet's syndrome; Sarcoidosis; Mucocutaneous lymph node syndrome; Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Mucocutaneous lymph node syndrome; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase III COVID 2019 infections
  • Discontinued Berylliosis; Hepatitis C; Pyoderma

Most Recent Events

  • 19 Oct 2022 Efficacy and adverse event data from the Phase III ACTIV-1 trial in COVID-2019 infections presented at the IDWeek 2022
  • 05 Mar 2022 Duke University in collaboration with Janssen completes the phase III ACTIV-1 trial in COVID-19 infections in USA, Argentina, Brazil, Mexico, Peru (IV) (NCT04593940)
  • 02 Jul 2019 Infliximab is not yet available for Crohn's disease and Ulcerative colitis in Taiwan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top